# Peking University Cancer Hospital

Source: https://onco.cc/institutions/pku-cancer-hospital/  
OnCo record `pku-cancer-hospital` (Institution). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

Beijing's dedicated cancer hospital and the leading Chinese centre for gastric cancer trials, where claudin 18.2 CAR-T and PD-1 combinations were first tested in gastric disease.

## Summary

Founded in 1976 as the Beijing Institute for Cancer Research, the hospital is Peking University's cancer centre and a nationally designated clinical speciality in gastrointestinal oncology, gastric surgery, lymphoma, melanoma and sarcoma. Lin Shen's GI oncology department has led or co-led the pivotal Chinese trials of PD-1 antibodies in gastric and oesophageal cancer, the first-in-human claudin 18.2 CAR-T study (satricabtagene autoleucel with CARsgen), and early ADC programmes. Jun Guo's melanoma group defined the biology and treatment of acral and mucosal melanoma, which dominate in East Asia. The hospital runs a large phase 1 unit and the Beijing cancer registry.

## Fields

- Kind: Institution
- Last checked: 2026-09-09
- Also known as: Beijing Cancer Hospital; Beijing Institute for Cancer Research; 北京大学肿瘤医院
- City: Beijing, CN
- Type: cancer-center
- Website: https://www.bjcancer.org

## Sources

- Peking University Cancer Hospital: https://www.bjcancer.org
- Peking University Health Science Center: https://www.bjmu.edu.cn

## Connected records

- cancers: [Colorectal cancer](https://onco.cc/cancers/colorectal/), [Diffuse large B-cell lymphoma](https://onco.cc/cancers/dlbcl/), [Gastric & gastro-oesophageal junction cancer](https://onco.cc/cancers/gastric/), [Melanoma](https://onco.cc/cancers/melanoma/), [Oesophageal cancer](https://onco.cc/cancers/esophageal/), [Sarcomas (soft tissue, bone, GIST)](https://onco.cc/cancers/sarcoma/)
- fronts: [Cell Therapy](https://onco.cc/fronts/cell-therapy/), [Immunotherapy](https://onco.cc/fronts/immunotherapy/)
- technologies: [Antibody-drug conjugate (ADC)](https://onco.cc/technologies/adc/), [CAR-T cell therapy](https://onco.cc/technologies/car-t/), [Immune checkpoint inhibitors](https://onco.cc/technologies/checkpoint-inhibitor/)
- targets: [Claudin 18.2](https://onco.cc/targets/cldn18-2/), [HER2](https://onco.cc/targets/her2/), [PD-1](https://onco.cc/targets/pd1/)
- drugs: [Disitamab vedotin](https://onco.cc/drugs/disitamab-vedotin/), [Satricabtagene autoleucel](https://onco.cc/drugs/satricabtagene-autoleucel/)
- companies: [CARsgen Therapeutics](https://onco.cc/companies/carsgen/), [RemeGen](https://onco.cc/companies/remegen/)
- collections: [CSCO guidelines (China)](https://onco.cc/collections/csco-guidelines/)
- people: [Changsong Qi](https://onco.cc/people/qi-changsong/), [Jun Guo](https://onco.cc/people/guo-jun/), [Lin Shen](https://onco.cc/people/shen-lin/), [Yuqin Song](https://onco.cc/people/yuqin-song/), [Ziyu Li](https://onco.cc/people/ziyu-li/)
- trials: [CT041-ST-01](https://onco.cc/trials/nct04581473/)
- key papers: [Claudin-18 isoform 2-specific CAR T-cell therapy (satri-cel) versus treatment of physician's choice for previously treated advanced gastric or gastro-oesophageal junction cancer (CT041-ST-01): a randomised, open-label, phase 2 trial](https://onco.cc/key-papers/paper-ct041-st-01-lancet-2025/)

---
JSON: https://onco.cc/api/v1/entities/pku-cancer-hospital.json